Two specific reversal agents for direct oral anticoagulants (DOACs) have been approved in
the United States: idarucizumab for dabigatran reversal and andexanet alfa for apixaban …

Non–vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin
for stroke prevention in atrial fibrillation and management of venous thromboembolism. In …

Background There is an increasing amount of literature on direct oral anticoagulant (DOAC)
laboratory monitoring. The aims of the present review were to evaluate published data on …

Measurement of direct oral anticoagulants (DOACs) activity is not routinely necessary.
Indeed, evaluation of DOACs plasmatic concentration is discouraged for the majority of …

Thrombotic events in children differ from those in adults in epidemiology, pathophysiology,
and anatomical location. However, anticoagulation in children is mostly based on evidence …

Introduction By increasing use of direct oral anticoagulants (DOACs) in adults and children,
gradual increase in the number of intentional or unintentional DOAC poisonings among …

Venous thromboembolism (VTE), which is characterized by pulmonary embolism and deep
vein thrombosis, has become a serious public concern. Notably, over half of the patients with …

Background Acute overdoses of apixaban, and other direct oral anticoagulants are relatively
uncommon. The number of direct oral anticoagulants prescriptions in the United States is …

Study objective In recent years, the use of novel anticoagulants and antiplatelet agents has
become widespread. Little is known about the toxicity and bleeding risk of these agents after …

Background Direct oral anticoagulants (DOAC) are widely used due to favourable
benefit/risk ratio. However, consequences of massive ingestion have been poorly …